Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...

Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine."Not MAHA at all!!!," the congresswoman wrote in a post on X, using the ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured ...

U.S. equities were mixed at midday after China accused the U.S. of violating a trade deal the two countries reached last ...

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.